The clinical validity, clinical utility and economic utility of the GeneSight Psychotropic test have been evaluated in multiple peer-reviewed publications. In fact, it’s the only neuropsychiatric pharmacogenomic test backed by such extensive research. It is important to note that not all patients who received a GeneSight Psychotropic test experienced improved outcomes. However, overall, GeneSight Psychotropic helped improve outcomes compared to treatment as usual in the following studies.
The GeneSight Psychotropic test analyzes how your genes may affect your response to medications commonly prescribed to treat depression, anxiety and other psychiatric conditions. The GeneSight Psychotropic test provides your clinician with information about which medications may require dose adjustments, may be less likely to work for you, or may have an increased risk of side effects based on your genetic makeup.
MTHFR is an enzyme required to convert folic acid and dietary folate into its active form, which is called l-methylfolate. L-methylfolate plays an important role in making neurotransmitters, such as serotonin, dopamine, and norepinephrine, which help regulate mood. The GeneSight MTHFR test shows whether a person has variation in MTHFR, which would limit their ability to create l-methylfolate.
The GeneSight test is administered in your office.
Insurance can be complicated, and we want patients to feel comfortable knowing what they'll owe. We promise that if the cost could be more than $330, we’ll call the patient before we process your test.
Our Learning Center provides educational information on a variety of topics related to the treatment of depression, pharmacogenomic testing and the GeneSight test.
These are some of those clinicians' stories...
The Montana Psychiatry Conference makes every attempt to provide accurate and timely content available for users. Neither MPC nor third-party content providers are responsible or liable for any such content, including advertising, products or other materials available through third party sites.